|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.910 HKD | -1.85% |
|
-0.29% | -6.62% |
| 20/01 | Ocumension Therapeutics Completes Patient Enrollment for OT-703 Real-World Study in Hainan, China | MT |
| 20/01 | Ocumension Therapeutics Completes Enrollment in the Real-World Study of OT-703 | CI |
| Capitalization | 496.19Cr 563.43Cr 72Cr 63Cr 57Cr 54Cr 98Cr 6.64TCr 102.11Cr 674.34Cr 267.97Cr 3.18TCr 270.04Cr 264.34Cr 11TCr | P/E ratio 2025 * |
-34.8x | P/E ratio 2026 * | 152x |
|---|---|---|---|---|---|
| Enterprise value | 458.22Cr 520.32Cr 66Cr 58Cr 52Cr 50Cr 91Cr 6.13TCr 94Cr 622.74Cr 247.46Cr 2.94TCr 249.38Cr 244.11Cr 11TCr | EV / Sales 2025 * |
5.55x | EV / Sales 2026 * | 4.14x |
| Free-Float |
36.97% | Yield 2025 * |
-
| Yield 2026 * | - |
| 1 day | -1.85% | ||
| 1 week | -0.29% | ||
| Current month | -8.36% | ||
| 1 month | -1.29% | ||
| 3 months | -15.21% | ||
| 6 months | -27.26% | ||
| Current year | -6.62% |
| 1 week | 6.66 |  | 7.13 |
| 1 month | 6.41 | | 7.63 |
| Current year | 6.41 | | 8.18 |
| 1 year | 3.91 | | 12.23 |
| 3 years | 3.62 | | 12.23 |
| 5 years | 3.62 | | 32.05 |
| 10 years | 3.62 | | 43 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 54 | 01/08/2018 |
Tim Ruan
DFI | Director of Finance/CFO | 40 | 12/01/2023 |
Yang Shen
CTO | Chief Tech/Sci/R&D Officer | 43 | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Yan Ling Cao
BRD | Director/Board Member | 42 | 18/06/2019 |
Ting Yuk Wu
BRD | Director/Board Member | 71 | 23/06/2020 |
Lian Yong Chen
CHM | Chairman | 63 | 20/07/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -0.29% | +43.66% | -24.73% | 73Cr | |
| +0.41% | -1.91% | +19.93% | +200.16% | 88TCr | |
| +0.69% | +0.25% | +49.34% | +57.88% | 58TCr | |
| +0.81% | -2.64% | +3.25% | +42.59% | 39TCr | |
| +0.50% | -5.54% | +5.40% | +21.46% | 32TCr | |
| -0.11% | -0.54% | +20.67% | +33.02% | 30TCr | |
| +0.07% | -1.48% | +26.04% | +60.91% | 29TCr | |
| +0.58% | -1.43% | +21.77% | +7.54% | 29TCr | |
| +0.01% | -2.84% | +15.47% | +56.14% | 20TCr | |
| +0.15% | -0.97% | +29.35% | +81.85% | 18TCr | |
| Average | +0.20% | -1.17% | +23.49% | +53.68% | 34.27TCr | |
| Weighted average by Cap. | +0.42% | -1.37% | +22.64% | +84.30% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 83Cr 94Cr 12Cr 10Cr 9.44Cr 9Cr 16Cr 1.1TCr 17Cr 112.12Cr 45Cr 528.47Cr 45Cr 44Cr 1.91TCr | 116.4Cr 132.18Cr 17Cr 15Cr 13Cr 13Cr 23Cr 1.56TCr 24Cr 158.2Cr 63Cr 745.62Cr 63Cr 62Cr 2.69TCr |
| Net income | -15Cr -17Cr -2.16Cr -1.88Cr -1.7Cr -1.62Cr -2.95Cr -199.07Cr -3.06Cr -20Cr -8.03Cr -95Cr -8.09Cr -7.92Cr -343.53Cr | 3.38Cr 3.83Cr 48.97L 42.65L 38.62L 36.84L 67.02L 45Cr 69.49L 4.59Cr 1.82Cr 22Cr 1.84Cr 1.8Cr 78Cr |
| Net Debt | -38Cr -43Cr -5.51Cr -4.8Cr -4.34Cr -4.14Cr -7.54Cr -508.3Cr -7.81Cr -52Cr -21Cr -243.19Cr -21Cr -20Cr -877.14Cr | -14Cr -16Cr -2.02Cr -1.76Cr -1.59Cr -1.52Cr -2.76Cr -186.41Cr -2.87Cr -19Cr -7.52Cr -89Cr -7.58Cr -7.42Cr -321.68Cr |
Employees
505
Sector
Pharmaceuticals
Calendar
26/03 -
Earnings release - Annual 2025
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | 6.910 $ | -1.85% | 4,24,000 |
| 13/26/13 | 7.040 $ | +3.53% | 32,20,000 |
| 12/26/12 | 6.800 $ | 0.00% | 3,18,691 |
| 11/26/11 | 6.800 $ | -1.45% | 4,30,777 |
| 10/26/10 | 6.900 $ | +2.37% | 6,80,000 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.085CNY
Average target price
8.803CNY
Spread / Average Target
+44.66%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1477 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition